Data gathered: December 21
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated December 20, 2024. Powered by Chat GPT.
X4 Pharmaceuticals, a biopharmaceutical company, is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Their pipeline includes multiple product candidates in various stages of clinical development. As a player in the healthcare sector, especially within the niche of rare disease therapeutics, X4 Pharmaceuticals is poised to potentially fill unmet medical needs with their innovative products.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | December 20 Price is up by 10.3% in the last 24h. |
|
X4 Pharmaceuticals | December 19 Price is down by -6.4% in the last 24h. |
|
X4 Pharmaceuticals | December 18 Price is down by -5.2% in the last 24h. |
|
X4 Pharmaceuticals | December 17 Price is up by 6.7% in the last 24h. |
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,069 | Sign up | Sign up | Sign up |
| Twitter Followers | 982 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 138 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $0.61 |
| Target Price | Sign up |
| Volume | 3,330,000 |
| Market Cap | $104M |
| Year Range | $0.28 - $1.36 |
| Dividend Yield | 0% |
| PE Ratio | 2.85 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Point72 Asset Management L.P. Boosts Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)December 13 - ETF Daily News |
|
X4 Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XFOR)December 11 - ETF Daily News |
 |
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & ExpositionDecember 4 - Investing.com |
 |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3 - Yahoo |
|
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNovember 26 - Investing.com |
|
B. Riley Research Analysts Raise Earnings Estimates for XFORNovember 21 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | 0.000 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | 93M | -0.070 |
| Q1 '24 | 0 | 0 | -19M | -52M | -37M | -0.260 |
| Q4 '23 | 24M | 9.9M | -12M | -19M | -25M | -0.100 |
| Q3 '23 | 0 | 0 | -9.7M | -2.3M | -26M | -0.010 |
Insider Transactions View All
| Ragan Paula filed to sell 1,025,816 shares at $0.6. October 16 '24 |
| Taveras Arthur filed to sell 388,026 shares at $0.6. October 8 '24 |
| DiBiase Mary filed to sell 452,060 shares at $0.6. October 8 '24 |
| Baldry Mark filed to sell 48,509 shares at $0.6. October 8 '24 |
| Ragan Paula filed to sell 1,057,713 shares at $0.5. October 8 '24 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $104M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 2.85.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $0.61.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.